4th International HIV/Viral Hepatitis Co-Infection Meeting
The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
22-23 July 2017, Paris, France


  • Overview
  • Organizing Committee
  • Partners
  • Programme
  • Abstract submission

The 4th International HIV/Viral Hepatitis Co-Infection Meeting is organized by the International AIDS Society (IAS) and will take place prior to the 9th IAS Conference on HIV Science (IAS 2017).

Building on the previous three successful annual meetings, the 4th International HIV/Viral Hepatitis Co-Infection Meeting will provide a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV. While the focus of the 3rd International HIV/Viral Hepatitis Co-Infection Meeting was on medical and access challenges in low- and middle-income settings in particular, the 4th meeting will also take advantage of the meeting location to explore the reality faced by people co-infected with HIV and viral hepatitis in high-income countries and across Eastern Europe and Central Asia. It will also be an opportunity to take stock of some of the scientific breakthroughs and brainstorm on concrete actions to support the WHO targets in their sector strategies.

The meeting will focus on addressing the challenges of achieving elimination of hepatitis B and C in HIV-infected populations worldwide through reviewing the latest information on epidemiology, prevention, diagnostics and treatment. Furthermore, the meeting will have a particular focus on access to care and new curative treatments especially for key populations with overlapping risk for both HIV and viral hepatitis, such as people who inject drugs, prisoners and men who have sex with men. These topics will be explored through a combination of keynote presentations to provide broad and assertive overviews of the different areas, invited and abstract-based oral and poster presentations to highlight cutting-edge science, and invited panel discussions and debates, with strong community participation, to go beyond the data and address the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.

Co-Chairs

Name
Organization
City
Marina Klein
McGill University and CIHR Canadian HIV Trials Network
Montreal, Canada
Karine Lacombe
Hôpital Saint-Antoine
Paris, France

Members

Name
Organization
City
Monique Andersson
Stellenbosch University, Faculty of Health Sciences
Cape Town, South Africa
Isabelle Andrieux-Meyer
Drugs for Neglected Diseases initiative
Geneva, Switzerland
Sanjay Bhagani
Royal Free Hospital
London, UK
Christoph Boesecke
University of Bonn
Bonn, Germany
Laurent Castera
Hôpital Beaujon
Paris, France
Greg Dore
Kirby Institute
Sydney, Australia
Jordan Feld
University of Toronto
Toronto, Canada
Niklas Luhmann
Médecins du Monde
Paris, France
Ludmila Maistat
Alliance for Public Health
Kiev, Ukraine
Gail Matthews
Kirby Institute
Sydney, Australia
Sébastien Morin
International AIDS Society
Geneva, Switzerland
Jacques Normand
National Institute on Drug Abuse
Washington D.C., USA
Jean-Michel Pawlotsky
Henri Mondor University Hospital
Créteil, France
Marion Peters
University of California
San Francisco, USA
Lionel Piroth
CHU Dijon Bourgogne
Dijon, France
Jürgen Rockstroh
University of Bonn
Bonn, Germany
Tracy Swan
Médecins Sans Frontières
New York, USA

See the programme here

Abstracts pertinent to HIV/viral hepatitis co-infection research (in particular around HIV co-infection with hepatitis B and C) can be considered for both IAS 2017 and the 4th International HIV/Viral Hepatitis Co-Infection Meeting. Please visit www.ias2017.org/Abstract-Submissions for more information.